Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or ...

Torex Gold Reports Year-End 2024 Reserves & ResourcesDrilling success continues to support reserve life extensionsMarch 19, 2025 6:00 PM EDT | Source: Torex Gold Resources Inc.(All amounts expressed in U.S. dollars unless otherwise stated)Toronto, Ontario--(Newsfile Corp. - March 19, 2025) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) is pleased to report year-end 2024 mineral reserves and resources for the Morelos Complex, which includes the producing El Limón Guajes ("ELG ...

10x Genomics' ATAC-Seq patents found valid and infringed PLEASANTON, Calif., March 3, 2025 /PRNewswire/ -- 10x Genomics (Nasdaq: TXG), a leader in single-cell and spatial biology, today provided an update on its patent litigation with Parse Biosciences. Through a consent agreement entered on February 25, 2025, in the United States District Court for the District of Delaware, Parse agreed - a week before trial was to start - to a worldwide permanent injunction that prevents it from making, using, selling or ...

Torex Gold Reports Excellent Drill Results from Media Luna West and Initial Results from Media Luna EastCompelling results return multiple high-grade intercepts at both Media Luna East and WestFebruary 24, 2025 6:00 AM EST | Source: Torex Gold Resources Inc.(All amounts expressed in U.S. dollars unless otherwise stated)Toronto, Ontario--(Newsfile Corp. - February 24, 2025) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) is pleased to provide results from the ongoing drilling ...

Core Insights - 10x Genomics announced new product innovations to enhance its leadership in single cell and spatial biology, aiming to support high-performance research at scale [1][2] - The company revealed a comprehensive product roadmap for its Visium and Xenium portfolios, focusing on advancements in spatial biology technology [1][3] Single Cell Innovations - The upcoming plate-based workflows for Chromium GEM-X Flex will allow researchers to process over 700 samples in a single run, recovering approximately 1 million cells from a single lane and 8 million cells per chip [3][5] - 10x Cloud Analysis for Large Studies will introduce batch analysis features for managing large datasets, enabling hundreds or thousands of analyses to run in parallel [3][5] - Recent innovations aim to democratize access to single cell analysis by providing high performance at low costs, including GEM-X Flex Gene Expression at one cent per cell and GEM-X Universal Multiplex for approximately $600 per sample [5][6] Spatial Biology Advancements - The Visium HD product launched in 2024 significantly increased resolution and is now compatible with various tissue types, enhancing sensitivity and sequencing efficiency [7][9] - Planned additions to the Visium HD platform include the Visium HD 3' assay for whole transcriptome spatial profiling and Visium HD Cell Segmentation for improved spatial transcriptomics data resolution [9][10] - The Xenium RNA+Protein Multiomics will enable simultaneous detection of RNA and proteins, enhancing multiomic insights into cellular functions [7][9] Company Events and Engagement - 10x Genomics will host a workshop at the AGBT meeting to share the latest developments and data across its platforms, with a live-stream option for remote participants [2][8] - The company is actively showcasing its technologies through scientific presentations and events at AGBT, emphasizing its role in driving biological discovery [8][11]

Torex Gold Reports Q4 and Full Year 2024 Results2024 marks another solid year of operational and financial results; on track to return to positive free cash flow generation by mid-2025February 19, 2025 6:00 PM EST | Source: Torex Gold Resources Inc.(All amounts expressed in U.S. dollars unless otherwise stated)Toronto, Ontario--(Newsfile Corp. - February 19, 2025) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) reports the Company's financial and operational results for the t ...

On Wednesday, 10x Genomics Inc TXG reported a fourth-quarter EPS loss of $(0.40), missing the consensus estimate of $(0.30).The single-cell and spatial biology company reported quarterly sales of $165.02 million, down 10% year over year, beating the consensus of $159.39 million.Gross margin was 67% for the fourth quarter of 2024 compared to 63% a year ago, primarily due to product mix changes.10x Genomics' instruments sales fell to $24.35 million from $38.4 million a year ago. This included $10.93 million f ...

10x Genomics, Inc. (NASDAQ:TXG) Q4 2024 Earnings Conference Call February 12, 2025 4:30 PM ET Company Participants Cassie Corneau - Senior Director, IR and Strategic Finance Serge Saxonov - CEO and Co-Founder Adam Taich - CFO Conference Call Participants Dan Brennan - TD Cowen Patrick Donnelly - Citi Dan Arias - Stifel Puneet Souda - Leerink Partners Doug Schenkel - Wolfe Research Tycho Peterson - Jefferies Tejas Savant - Morgan Stanley Dan Leonard - UBS Subbu Nambi - Guggenheim Securities Kyle Mikson - Can ...

10x Genomics (TXG) came out with a quarterly loss of $0.40 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.41 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -25%. A quarter ago, it was expected that this life science technology company would post a loss of $0.34 per share when it actually produced a loss of $0.30, delivering a surprise of 11.76%.Over the last four quarters, the co ...

Financial Performance - For the year ended December 31, 2024, 10x Genomics, Inc. recognized revenues of $610.8 million[411]. - Revenue for the year ended December 31, 2024, was $610.785 million, a decrease of 1.5% from $618.727 million in 2023[416]. - Revenue from consumables increased to $493.432 million in 2024, compared to $479.553 million in 2023, driven by a rise in spatial consumables revenue[492]. - Net loss for 2024 was $182.627 million, an improvement from a net loss of $255.099 million in 2023, representing a 28.4% reduction[419]. - Net loss per share improved to $(1.52) in 2024 from $(2.18) in 2023[416]. - The company reported net cash provided by operating activities of $6.664 million in 2024, a significant improvement from a net cash used of $(15.197) million in 2023[424]. - The company’s total comprehensive loss for 2024 was $182.691 million, compared to $251.193 million in 2023, showing a reduction of approximately 27.3%[419]. Assets and Liabilities - As of December 31, 2024, total assets were $918.6 million, a decrease from $965.1 million in 2023[414]. - Cash and cash equivalents decreased to $344.1 million in 2024 from $359.3 million in 2023[414]. - Accounts receivable, net, decreased to $87.9 million in 2024 from $114.8 million in 2023[414]. - Total stockholders' equity decreased to $710.1 million in 2024 from $741.0 million in 2023[414]. - Cash, cash equivalents, and restricted cash at the end of 2024 were $344.067 million, down from $359.284 million at the end of 2023[424]. - Inventory increased to $83.1 million as of December 31, 2024, up from $73.7 million in 2023, with purchased materials and work in progress contributing to the rise[481]. - Property and equipment, net decreased to $252.6 million as of December 31, 2024, from $279.6 million in 2023, with depreciation expense recorded at $33.9 million for the year[482]. Expenses - Total operating expenses decreased to $609.041 million in 2024 from $674.642 million in 2023, a reduction of approximately 9.7%[416]. - Stock-based compensation expense for 2024 was $140.749 million, compared to $166.950 million in 2023, indicating a decrease of about 15.7%[424]. - Research and development expenses were incurred for personnel, independent contractors, and laboratory supplies, with no specific dollar amount provided in the extracted content[455]. - Advertising costs increased to $3.9 million in 2024 from $3.3 million in 2023, while 2022 costs were $3.7 million[457]. Foreign Currency and Interest Rate Risks - Approximately 27% of sales in 2024 were denominated in currencies other than U.S. dollars, compared to 23% in 2023[397]. - A hypothetical 100 basis-point increase in interest rates would have adversely affected the fair value of the investment portfolio by approximately $0.2 million in 2024[396]. - The Company has exposure to foreign currency exchange risk, with a hypothetical 10% movement in exchange rates potentially changing cash and cash equivalents by approximately $4.2 million in 2024[398]. - The Company recognized foreign currency transaction losses of $2.1 million for the year ended December 31, 2024, compared to gains of $1.2 million and $0.2 million for the years ended December 31, 2023 and 2022, respectively[463]. Legal Matters - A jury awarded the Company more than $31 million in damages from NanoString, consisting of approximately $25 million in lost profits and approximately $6 million in royalties[518]. - NanoString filed a lawsuit against the Company alleging infringement of U.S. Patent No. 11,473,142, seeking injunctive relief and unspecified damages[523]. - The Munich Regional Court found that NanoString's CosMx products infringe EP Patent No. 2794928B1, issuing a permanent injunction effective June 1, 2023[525]. - The Company filed requests for preliminary injunctions in the Unified Patent Court alleging infringement of EP Patents 928 and 782, with the UPC granting the injunction for EP782 on September 19, 2023[527]. - The trial for the NanoString action is scheduled for November 2024, with discovery currently in progress[523]. - The Company filed a lawsuit against Vizgen alleging infringement of multiple U.S. Patents, with discovery ongoing and a Markman hearing held on January 10, 2024[530]. Stock and Equity - The Company has authorized the issuance of 1,200,000,000 shares of capital stock, including 1,000,000,000 shares of Class A common stock[540]. - As of December 31, 2024, the number of shares of Class A common stock issuable under the Amended and Restated 2012 Stock Plan was 1,842,338[542]. - The total intrinsic value of stock options exercised was $12.3 million for the year ended December 31, 2024, compared to $78.0 million in 2023 and $89.5 million in 2022[546]. - The total unrecognized stock-based compensation related to stock options as of December 31, 2024, was $19.5 million, expected to be recognized over approximately two years[546]. - The total unrecognized stock-based compensation related to restricted stock units (RSUs) was $194.4 million as of December 31, 2024, to be recognized over approximately three years[548]. - A total of 385,967 shares of Class A common stock were issued under the ESPP for the year ended December 31, 2024[559]. - The maximum number of shares available under the ESPP is 3,686,671, with 2,705,096 shares available for issuance as of December 31, 2024[559]. Tax Positions - The provision for income taxes for the year ended December 31, 2024, was $4.927 million, a decrease from $6.336 million in 2023[494]. - The company’s total deferred tax assets were $496.171 million as of December 31, 2024, with a full valuation allowance maintained on U.S. net deferred tax assets[496]. - The total amount of unrecognized gross tax benefits was $50.0 million as of December 31, 2024, compared to $45.7 million in 2023, with $2.9 million and $2.7 million potentially affecting the effective tax rate if recognized[500]. Commitments and Contingencies - The Company has commitments to make a total of $13.2 million in purchases over the next year as of December 31, 2024[507]. - The Company has entered into non-cancelable arrangements for subscription software services totaling $19.6 million over the next five years[508]. - The Company incurred operating lease costs of $12.6 million, $13.6 million, and $13.1 million for the years ended December 31, 2024, 2023, and 2022, respectively[513]. - The total lease payments due under the Company's operating lease liabilities as of December 31, 2024, amount to $101.2 million[514].